{"id":"NCT01732471","sponsor":"Merck KGaA, Darmstadt, Germany","briefTitle":"Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria","officialTitle":"A Phase III Non-comparative Open-label Clinical Study to Evaluate the Response to and Safety of Kuvan (Sapropterin Dihydrochloride) After 6 Weeks of Treatment in Patients of 4 to 18 Years of Age With Phenylketonuria Who Have Elevated Blood Phenylalanine Levels","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2012-11-22","resultsPosted":"2014-07-28","lastUpdate":"2014-07-28"},"enrollment":90,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Phenylketonuria"],"interventions":[{"type":"DRUG","name":"Kuvan®","otherNames":["Sapropterin dihydrochloride","6R-BH4 tetrahydrobiopterin"]}],"arms":[{"label":"Kuvan®","type":"EXPERIMENTAL"}],"summary":"This is an open-label, non-comparative, Phase 3 study to evaluate the degree, frequency of response and safety of Kuvan® (sapropterin dihydrochloride) in subjects aged 4 to 18 years who have phenylketonuria and with elevated blood phenylalanine level of greater than or equal to 450 micromole per liter.","primaryOutcome":{"measure":"Percentage of Participants With Response to Kuvan® (Sapropterin Dihydrochloride) Treatment","timeFrame":"Day 8","effectByArm":[{"arm":"Kuvan®","deltaMin":33.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":90},"commonTop":["Respiratory tract infection viral","Phenylketonuria","Respiratory tract infection","Retinal vascular disorder","Anaemia"]}}